Imfinzi-Imjudo (durvalumab-tremelimumab)

pCPA File Number: 23152
Negotiation Status:
Under consideration for negotiation
Indication(s):
In combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CDA-AMC Project Number:
PC0390-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable